"While tirzepatide causes considerable weight loss, research is lacking on its effects on cardiovascular ... Researchers utilized the Kansas City Cardiomyopathy Questionnaire clinical summary score, a ...
Real-world data on GLP-1R agonists’ safety in heart failure and CKD patients was investigated using the TriNetX Research ...
The Company is seeking approval of tirzepatide for the treatment of HFpEF and obesity and has submitted data to the FDA. Detailed results were announced from a phase 3 clinical trial evaluating the ...
In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...
In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...
The results from the SUMMIT trial of tirzepatide in obese patients with heart failure ... a nearly 25-point improvement in ...
GlobalData on MSN11h
Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEFThe trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.
In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...
But for diabetes and obesity drugs like Ozempic and Zepbound, known as GLP-1s, cheaper copycats emerged almost ...
Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly ...
HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...
CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback